tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

RGNX Stock Latest News

RegenXBio: Clinical Hold on RGX-111/121 Seen as Manageable Timing Issue, Core Gene Therapy Platform and Key Value Drivers Remain Intact Supporting Buy Rating
RatingsRegenXBio: Clinical Hold on RGX-111/121 Seen as Manageable Timing Issue, Core Gene Therapy Platform and Key Value Drivers Remain Intact Supporting Buy Rating
3d ago
RGNX
Stifel says Regenxbio’s RGX-121 delay not unexpected, not difficult to resolve
PremiumThe Fly
Stifel says Regenxbio’s RGX-121 delay not unexpected, not difficult to resolve
3d ago
RGNX
Midday Fly By: AT&T reports Q4 beat, Amazon cuts 16,000 jobs
PremiumThe Fly
Midday Fly By: AT&T reports Q4 beat, Amazon cuts 16,000 jobs
3d ago
T
V
Regenxbio selloff ‘an overreaction’ to clinical hold, says Leerink
PremiumThe Fly
Regenxbio selloff ‘an overreaction’ to clinical hold, says Leerink
4d ago
RGNX
Regenxbio clinical hold does not change thesis, says Clear Street
PremiumThe Fly
Regenxbio clinical hold does not change thesis, says Clear Street
4d ago
RGNX
FDA Halts RegenXBio MPS Gene Therapy Trials
PremiumCompany AnnouncementsFDA Halts RegenXBio MPS Gene Therapy Trials
4d ago
8K
RGNX
Regenxbio announces FDA places clinical hold on RGX-111
Premium
The Fly
Regenxbio announces FDA places clinical hold on RGX-111
4d ago
RGNX
Regenxbio down 35% to $8.59 after FDA places clinical hold on RGX-111
Premium
The Fly
Regenxbio down 35% to $8.59 after FDA places clinical hold on RGX-111
4d ago
RGNX
Regenxbio announces FDA places clinical hold of RGX-111
PremiumThe Fly
Regenxbio announces FDA places clinical hold of RGX-111
4d ago
RGNX
Regenxbio assumed with an Overweight at Barclays
PremiumThe Fly
Regenxbio assumed with an Overweight at Barclays
4d ago
RGNX
RegenXBio: Advancing Gene Therapy Pipeline and Near‑Term Regulatory Catalysts Underpin Buy Rating
PremiumRatings
RegenXBio: Advancing Gene Therapy Pipeline and Near‑Term Regulatory Catalysts Underpin Buy Rating
19d ago
RGNX
Regenxbio highlights progress, anticipated milestones
PremiumThe Fly
Regenxbio highlights progress, anticipated milestones
20d ago
RGNX
Regenxbio price target raised to $28 from $20 at BofA
PremiumThe FlyRegenxbio price target raised to $28 from $20 at BofA
26d ago
RGNX
3 ‘Strong Buy’ Biotech Stocks to Buy Now, According to Top Analysts
Premium
Market News
3 ‘Strong Buy’ Biotech Stocks to Buy Now, According to Top Analysts
1M ago
PYXS
RGNX
Regenxbio price target raised to $45 from $40 at Stifel
Premium
The Fly
Regenxbio price target raised to $45 from $40 at Stifel
1M ago
RGNX
Regenxbio price target raised to $20 from $16 at Leerink
PremiumThe Fly
Regenxbio price target raised to $20 from $16 at Leerink
2M ago
RGNX
RegenXBio’s Strategic Positioning and Advancements Drive Buy Rating Amid Market Opportunities
PremiumRatings
RegenXBio’s Strategic Positioning and Advancements Drive Buy Rating Amid Market Opportunities
2M ago
RGNX
RegenXBio’s Gene Therapy Study for Hunter Syndrome: A Potential Game-Changer
PremiumCompany Announcements
RegenXBio’s Gene Therapy Study for Hunter Syndrome: A Potential Game-Changer
2M ago
RGNX
Regenxbio files $300M mixed securities shelf
PremiumThe Fly
Regenxbio files $300M mixed securities shelf
2M ago
RGNX
RegenXBio’s Strategic Manufacturing and Commercial Readiness Justifies Buy Rating and $34 Price Target
PremiumRatingsRegenXBio’s Strategic Manufacturing and Commercial Readiness Justifies Buy Rating and $34 Price Target
3M ago
RGNX
RegenXBio’s Strategic Manufacturing Edge and Market Position Justify Buy Rating
Premium
Ratings
RegenXBio’s Strategic Manufacturing Edge and Market Position Justify Buy Rating
3M ago
RGNX
RegenXBio Inc. Earnings Call: Positive Progress Amid Challenges
Premium
Company Announcements
RegenXBio Inc. Earnings Call: Positive Progress Amid Challenges
3M ago
RGNX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >